Reports Q3 revenue $27.76M, consensus $29.01M. “Arrowhead (ARWR) continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 studies. In addition, our commercial buildout is designed to make us launch ready on day one, should plozasiran receive regulatory approval on the November 18, 2025, PDUFA date,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. “We continue to maintain a strong balance sheet, which we believe gives us the financial resources to move multiple innovative new medicines through the clinical and regulatory process and ultimately get them to the patients who need them.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 Earnings Cheat Sheet
- Arrowhead announces asset purchase agreement between Sanofi, Visirna
- Strategic Collaboration with Sarepta Boosts Arrowhead Pharmaceuticals’ Buy Rating
- Cautious Hold Rating for Arrowhead Pharmaceuticals Amid SRPT Developments and Market Uncertainties
- Sarepta tells Bloomberg expects to honor Arrowhead commitments